Efficacy of first-line bleomycin, etoposide, and cisplatin chemotherapy for peripheral blood stem cell mobilization in patients with germ cell cancer

1998 ◽  
Vol 3 (3) ◽  
pp. 147-151 ◽  
Author(s):  
Yuji Yamada ◽  
Isao Hara ◽  
Kazuo Gohji ◽  
Ichiro Nakamura ◽  
Yasuhiko Oka ◽  
...  
Keyword(s):  
Stem Cell ◽  
Germ Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Cell Cancer ◽  
Germ Cell Cancer ◽  
Blood Stem Cell ◽  
Stem Cell Mobilization ◽  
First Line ◽  
Cell Mobilization

Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+cell count to guide pre-emptive or immediate rescue mobilization.

Cytotherapy ◽  
2012 ◽  
Vol 14 (7) ◽  
pp. 823-829 ◽  
Author(s):  
Juan-Manuel Sancho ◽  
Mireia Morgades ◽  
Joan-Ramon Grifols ◽  
Jordi Juncà ◽  
Ramon Guardia ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Count ◽  
Predictive Factors ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Stem Cell Mobilization ◽  
Cell Mobilization

scholarly journals The Effect of Febrile Neutropenia During Peripheral Blood Stem Cell Mobilization on Stem Cell Harvest and Stem Cell Mobilization

LLM Dergi ◽  
2018 ◽  
Vol 2 (3) ◽  
pp. 71-76
Author(s):  
Cemaleddin ÖZTÜRK ◽  
Pervin TOPÇUOĞLU ◽  
Klara DALVA ◽  
Osman İLHAN ◽  
Muhit ÖZCAN
Keyword(s):  
Stem Cell ◽  
Febrile Neutropenia ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Stem Cell Mobilization ◽  
Cell Mobilization ◽  
Cell Harvest

Peripheral Blood Stem Cell Mobilization Tactics

2010 ◽  
Vol 44 (1) ◽  
pp. 107-116 ◽  
Author(s):  
Lindsay L Rosenbeck ◽  
Shivani Srivastava ◽  
Patrick J Kiel
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Stem Cell Mobilization ◽  
Cell Mobilization

Single Center Experience of a New Intensive Induction Therapy for Ewing’s Family of Tumors: Feasibility, Toxicity, and Stem Cell Mobilization Properties

2003 ◽  
Vol 21 (15) ◽  
pp. 2974-2981 ◽  
Author(s):  
S.J. Strauss ◽  
A. McTiernan ◽  
D. Driver ◽  
M. Hall-Craggs ◽  
A. Sandison ◽  
...  
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Dose Intensity ◽  
Infectious Complications ◽  
Blood Stem Cell ◽  
Stem Cell Mobilization ◽  
Induction Regimen ◽  
Cell Mobilization ◽  
Ewing's Family Of Tumors

Purpose: To examine the feasibility, tolerability, and toxicity of an intensified induction regimen (vincristine, ifosfamide, doxorubicin, and etoposide [VIDE]) in patients with newly diagnosed Ewing’s family of tumors (EFT); to assess ability to maintain dose-intensity, and predictability of peripheral-blood stem cell mobilization. Patients and Methods: Thirty patients were treated with vincristine 1.4 mg/m2 (maximum 2 mg) on day 1, doxorubicin 20 mg/m2, ifosfamide 3 g/m2 plus mesna and etoposide 150 mg/m2 on days 1 to 3. Cycles were given every 21 days for up to six cycles. Results: One-hundred and seventy cycles of VIDE were given. The median treatment interval was 21 days (21 to 42) and nadir count: hemoglobin 8.3 (6.3 to 11.9), neutrophils 0.045 (0.0 to 2.1), and platelets 45 (3 to 343). There were 96 episodes of infection requiring hospitalization (56%). Growth factor support reduced infectious complications by 34%. Etoposide dose was reduced, or omitted, in 24% of cycles. Four patients did not complete six cycles due to unacceptable toxicity and one patient progressed on treatment. Twenty patients underwent peripheral-blood stem cell harvesting, 15 after cycle 3, and five after cycle 4. Median CD34+ yield was 4.6 × 106/kg per patient (1.8 to 14.5). Overall response to treatment, measured in 24 patients, was 88%. Seven of 11 patients undergoing surgery achieved greater than 90% necrosis of tumor (64%). Conclusion: VIDE is an effective induction regimen with substantial but acceptable toxicity that allows predictable mobilization of stem cells. Maintenance of dose-intensity is feasible in the majority of patients. Growth factors play a role in maintaining dose-intensity and reduce infectious complications.

Sign in / Sign up

Export Citation Format

Share Document